Research ExplorerPublicationsDrug delivery in acute myeloid leukemia

Drug delivery in acute myeloid leukemia

Standard

Drug delivery in acute myeloid leukemia. / Kohlschütter, Johannes; Michelfelder, Stefan; Trepel, Martin.

In: EXPERT OPIN DRUG DEL, Vol. 5, No. 6, 06.2008, p. 653-63.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Kohlschütter, J, Michelfelder, S & Trepel, M 2008, 'Drug delivery in acute myeloid leukemia', EXPERT OPIN DRUG DEL, vol. 5, no. 6, pp. 653-63. https://doi.org/10.1517/17425247.5.6.653

APA

Kohlschütter, J., Michelfelder, S., & Trepel, M. (2008). Drug delivery in acute myeloid leukemia. EXPERT OPIN DRUG DEL, 5(6), 653-63. https://doi.org/10.1517/17425247.5.6.653

Vancouver

Kohlschütter J, Michelfelder S, Trepel M. Drug delivery in acute myeloid leukemia. EXPERT OPIN DRUG DEL. 2008 Jun;5(6):653-63. https://doi.org/10.1517/17425247.5.6.653

Bibtex

@article{4a4fa034dc8443e5a429fa9db09a93a8,
title = "Drug delivery in acute myeloid leukemia",
abstract = "BACKGROUND: Acute myeloid leukemia was among the first malignancies to be cured by drug therapy alone, but overall survival rates remain unsatisfactory and have changed little over the past 20 years. Conventional chemotherapeutic regimens, which almost invariably include cytarabine and anthracyclines, are untargeted, and more specific therapies are needed.OBJECTIVE: We have chosen acute myeloid leukemia as a disease prototype to review established and novel targeted approaches in leukemia treatment.METHODS: Our selection of the reviewed literature focused on drug delivery aspects.CONCLUSION: While the toxicity profile of chemotherapeutics has been improved by liposomal formulations and antibody conjugation for leukemia-directed uptake, their efficacy has probably not changed significantly. Drugs with an alternative mode of action, including kinase inhibitors, hold great promise. Further improvements may result from the characterization of novel acute myeloid leukemia (AML) cell surface receptors and of leukemic stem cells, as well as from the design of leukemia-targeted gene therapy vectors.",
keywords = "Antibodies, Monoclonal, Antigens, CD, Antigens, Differentiation, Myelomonocytic, Antineoplastic Agents, Drug Delivery Systems, Genetic Therapy, Humans, Integrin alpha4beta1, Leukemia, Myeloid, Acute, Liposomes, Neoplastic Stem Cells, Sialic Acid Binding Ig-like Lectin 3, Journal Article, Review",
author = "Johannes Kohlsch{\"u}tter and Stefan Michelfelder and Martin Trepel",
year = "2008",
month = jun,
doi = "10.1517/17425247.5.6.653",
language = "English",
volume = "5",
pages = "653--63",
number = "6",

}

RIS

TY - JOUR

T1 - Drug delivery in acute myeloid leukemia

AU - Kohlschütter, Johannes

AU - Michelfelder, Stefan

AU - Trepel, Martin

PY - 2008/6

Y1 - 2008/6

N2 - BACKGROUND: Acute myeloid leukemia was among the first malignancies to be cured by drug therapy alone, but overall survival rates remain unsatisfactory and have changed little over the past 20 years. Conventional chemotherapeutic regimens, which almost invariably include cytarabine and anthracyclines, are untargeted, and more specific therapies are needed.OBJECTIVE: We have chosen acute myeloid leukemia as a disease prototype to review established and novel targeted approaches in leukemia treatment.METHODS: Our selection of the reviewed literature focused on drug delivery aspects.CONCLUSION: While the toxicity profile of chemotherapeutics has been improved by liposomal formulations and antibody conjugation for leukemia-directed uptake, their efficacy has probably not changed significantly. Drugs with an alternative mode of action, including kinase inhibitors, hold great promise. Further improvements may result from the characterization of novel acute myeloid leukemia (AML) cell surface receptors and of leukemic stem cells, as well as from the design of leukemia-targeted gene therapy vectors.

AB - BACKGROUND: Acute myeloid leukemia was among the first malignancies to be cured by drug therapy alone, but overall survival rates remain unsatisfactory and have changed little over the past 20 years. Conventional chemotherapeutic regimens, which almost invariably include cytarabine and anthracyclines, are untargeted, and more specific therapies are needed.OBJECTIVE: We have chosen acute myeloid leukemia as a disease prototype to review established and novel targeted approaches in leukemia treatment.METHODS: Our selection of the reviewed literature focused on drug delivery aspects.CONCLUSION: While the toxicity profile of chemotherapeutics has been improved by liposomal formulations and antibody conjugation for leukemia-directed uptake, their efficacy has probably not changed significantly. Drugs with an alternative mode of action, including kinase inhibitors, hold great promise. Further improvements may result from the characterization of novel acute myeloid leukemia (AML) cell surface receptors and of leukemic stem cells, as well as from the design of leukemia-targeted gene therapy vectors.

KW - Antibodies, Monoclonal

KW - Antigens, CD

KW - Antigens, Differentiation, Myelomonocytic

KW - Antineoplastic Agents

KW - Drug Delivery Systems

KW - Genetic Therapy

KW - Humans

KW - Integrin alpha4beta1

KW - Leukemia, Myeloid, Acute

KW - Liposomes

KW - Neoplastic Stem Cells

KW - Sialic Acid Binding Ig-like Lectin 3

KW - Journal Article

KW - Review

U2 - 10.1517/17425247.5.6.653

DO - 10.1517/17425247.5.6.653

M3 - SCORING: Review article

C2 - 18532921

VL - 5

SP - 653

EP - 663

IS - 6

ER -